Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
2
self-reported band not used
Founded
Not recorded
Legal entities
1
ABR
Office countries
1
1 address
Funding rounds
None on record
Company type
Public Company
self-reported
Legal entity
1 brand → 1 confirmed entity
VECTUS BIOSYSTEMS LIMITED
ABN54117526137
Legal entities
Show as table · Vectus Biosystems: 1 registry entity
| VECTUS BIOSYSTEMS LIMITED | ABN 54117526137 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Vectus Biosystems Limited (ASX:VBS) is developing a treatment for fibrosis and high blood pressure, which includes the treatment for three of the largest diseases in the fibrotic market, namely heart, kidney and liver diseases. Vectus successfully completed its Initial Public Offering (IPO) on the Australian Securities Exchange (ASX:VBS) and commenced trading on ASX on 23 February 2016, after raising A$5.1 million. Funds from the IPO were predominantly used to develop the Company’s lead compound, VB0004, which aims to treat the hardening of functional tissue and high blood pressure. Vectus has conducted a range of successful pre-clinical trials, which have shown that VB0004 slows down the advances of fibrosis, potentially repairs damaged cell tissue and reduces high blood pressure. VB0004 is now progressing through a number of important milestones, including pharmaceutical scale-up and additional toxicity studies. Following successful results, the late 2019 convertible note fundraising, and the late 2020 share placement, the Company has funding for its Human Phase I trial. Vectus’ strategy is to develop and perform early validation of its drug candidates to the point where they may become commercially attractive to potential pharmaceutical partners.
The Company has also developed technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The technology, called Accugen, is owned by Vectus’ wholly-owned subsidiary Accugen Pty Limited. The technology offers a time, cost and accuracy benefit compared to currently-available systems.
The Company’s current stage of investment in Accugen is a commercialisation programme that may include direct sales, distribution partnerships and licensing opportunities.
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
Addresses
- AU3-11 Primrose Avenue; Rosebery, NSW 2018Primary
Grid intelligence Members
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
FAQ
Which legal entity operates under Vectus Biosystems?
One New South Wales entity on the ABR: VECTUS BIOSYSTEMS LIMITED (ABN 54 117 526 137), high confidence.
How many people work at Vectus Biosystems?
2 counted staff profiles at January 2026. The brand's self-reported band sits above that count and is not published as a headcount.
Where does Vectus Biosystems have offices?
1 address on record.
Has Vectus Biosystems raised funding?
None linked to this brand.
Which companies are listed alongside Vectus Biosystems?
4 profiles list Vectus Biosystems as a peer — 56th percentile in Biotechnology Research. It lists ten peers of its own. Accugen Pty Ltd and Visionflex - The virtual care experts. list it back.